Table 1 Baseline characteristics of the CHC patients before anti-HCV treatment.
Parameters | All patients (N = 1090) | SVR(+) (N = 990) | SVR(−) (N = 100) | P-valuea SVR(+) vs. SVR(−) |
|---|---|---|---|---|
Male | 490(45%) | 44(44.9%) | 45(45%) | 0.992 |
Age, years | 48(40–57) | 48(40–57) | 49(40–56) | 0.993 |
Genotype | ||||
1 | 718(65.9%) | 650(65.7%) | 68(68%) | 0.610 |
2 | 50(4.6%) | 48(4.8%) | 2(2%) | |
3 | 84(7.7%) | 77(7.8%) | 7(7%) | |
Others and unknown | 238(21.8%) | 215(21.7%) | 23(23%) | |
HCV-RNA, log IU/mL | 6.06(5.10–6.55) | 6.05(5.11–6.54) | 6.20(4.64–6.66) | 0.419 |
FPG, mmol/L | 5.31(4.94–5.85) | 5.31(4.93–5.85) | 5.34(5.02–5.83) | 0.364 |
Prediabetes | 278(25.5%) | 250(25.2%) | 28(28%) | 0.537 |
Diabetes | 89(8.16%) | 82(8.28%) | 7(7%) | |
TBiL, μmol/L | 15.2(11.5–20.6) | 15.2(11.5–20.5) | 15.6(10.92–21.4) | 0.822 |
ALT, IU/L | 49(26–98) | 49(26–99) | 47(27–84) | 0.594 |
AST, IU/L | 45(30–78) | 46(46–79) | 42(30–76.75) | 0.867 |
ALB, g/L | 44(41.1–46.5) | 44.1(41.2–46.6) | 43.25(40.80–45.47) | 0.038b |
ALP, IU/L | 82(68–106) | 82(67–106) | 86.50(71–105.75) | 0.218 |
GGT, IU/L | 34.50(19–76) | 34(19–73.25) | 39.5(39.5–81.75) | 0.301 |
Hb, g/L | 136(123–150) | 137(123.75–150) | 131.5(111.5–142) | 0.003b |
PLTs, 109/L | 121(85–165) | 123(86–166) | 111(72.25–156.50) | 0.147 |
WBCs, 109/L | 5.02(3.91–6.35) | 5.07(3.98–6.42) | 4.34(4.34–5.655) | <0.001b |
APRI | 0.99(0.54–1.99) | 0.98(0.54–1.98) | 1.17(0.55–2.21) | 0.522 |
FIB-4 | 2.63(1.49–5.09) | 2.61(1.47–5.08) | 2.69(1.73–5.28) | 0.315 |
